ASCO GI 2025

January 23-25, 2025
San Francisco, CA

ASCO Gastrointestinal Cancer Symposium 2025

Explore more Oncology congress materials

Results(2)

Oncology

Zanidatamab Dose optimization in Patients With HER2-Positiva Biliary Tract Cancer

Author(s): Sheryl Trueman, Liviawati Wu, Suzette Girgis et al.

HERIZON-BTC-302: A Phase 3 Study of Zanidatamab With Standard-of-Care Therapy vs Standard-of-Care Alone For First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Positive Advanced/Metastatic Biliary Tract Cancer

Author(s): James J. Harding, Teresa Macarulla, Shubham Pant et al.

Disclaimer

This AI model is continuing to learn and its responses are based on learned data patterns. It should not replace professional judgment. Please verify the information before use, and feedback is welcome to improve its accuracy.

Please do not include personal or confidential information in your searches. For information on how to report an adverse event or product complaint for a Jazz product, please visit: https://www.jazzpharma.com/medicines/drug-safety/.